Showing results (1-10 of 41) with videos related to
Sort By:
Pageof 5
Molecular & Cellular Oncology|September 22, 2016
Co-activation of AMPK and mTORC1 as a new therapeutic option for acute myeloid leukemiaPierre Sujobert, Jerome TamburiniExpert Opinion on Investigational Drugs|October 9, 2013
Predicting effects of kinase inhibitor in therapy for myeloid malignancies - the challenges in capturing disease heterogeneityHåkon Reikvam, Ina Nepstad, Jerome TamburiniInternational Journal of Molecular Sciences|August 28, 2020
Drug Resistance in Hematological MalignanciesPatrick Auberger, Jerome Tamburini-Bonnefoy, Alexandre PuissantFrontiers in Oncology|June 14, 2019
Rationale for Targeting Deregulated Metabolic Pathways as a Therapeutic Strategy in Acute Myeloid LeukemiaNicolas Chapuis, Laury Poulain, Rudy Birsen, et al.Current Oncology Reports|February 22, 2012
PI3K and mTOR signaling pathways in cancer: new data on targeted therapiesLise Willems, Jerome Tamburini, Nicolas Chapuis, et al.Cell Cycle (Georgetown, Tex.)|May 17, 2011
LKB1/AMPK/mTOR signaling pathway in hematological malignancies: from metabolism to cancer cell biologyAlexa S Green, Nicolas Chapuis, Catherine Lacombe, et al.Haematologica|June 14, 2006
Single cell analysis of phosphoinositide 3-kinase/Akt and ERK activation in acute myeloid leukemia by flow cytometryValérie Bardet, Jerome Tamburini, Norbert Ifrah, et al.Cell Cycle (Georgetown, Tex.)|November 26, 2009
Targeting translation in acute myeloid leukemia: a new paradigm for therapy?Jerome Tamburini, Alexa S Green, Nicolas Chapuis, et al.Cancers|December 10, 2021
AMP-Activated Protein Kinase Contributes to Apoptosis Induced by the Bcl-2 Inhibitor Venetoclax in Acute Myeloid LeukemiaNoémie Legrand, Amandine Pradier, Laury Poulain, et al.World Journal of Radiology|June 29, 2013
Helical tomotherapy and systemic targeted therapies in solitary plasmacytoma: Pilot studyNadia Wiazzane, Cyrus Chargari, Corine Plancher, et al.Pageof 5